Abstract
To mitigate the unprecedented health, social, and economic damage of COVID-19, the Philippines implemented a nation-wide vaccine program to mitigate the effects of the global pandemic. In a previous study, we interrogated COVID-19 vaccine intent in the country by deploying a nationwide open-access online survey, two months before the initial rollout of the national vaccination program that began in March of 2021. In this follow-up study, we explored the influence of the ongoing vaccine rollout on vaccine intent by deploying a similar survey six months after the initial rollout of vaccines had begun throughout the archipelago. Our data suggests that the presence of vaccines and vaccinated individuals in a Filipino community predicts vaccination intent. When directly asked if they were more willing to receive a vaccination than six months prior, 92.26% agreed to some extent that they were indeed more willing. Finally, despite the changes in the numbers of respondents who were more open to the COVID-19 vaccines, there were no significant changes in the predictive power of our Health Belief Model (HBM) constructs. For the most part, the HBM factors that predicted vaccination intent in our earlier study also predicted vaccination intent in this current study.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
N/A
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our study protocol (Protocol Number 21-026) was reviewed and approved by the Institutional Review Board of Providence College on January 15, 2021, with an amendment for the current study being reviewed and approved on July 15, 2021. Originally, we had sought ethical review at the University of Santo Tomas in the Philippines for our initial study but were advised by university authorities there to seek accelerated IRB approval in the United States due to the impact of the then ongoing-COVID-19 pandemic.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors. They will be included in the final publication in a peer-reviewed journal.
